E156 Micro-Paper · Africa Clinical Trials

Altruism Efficiency & Health Expenditure

Africa gives the most research participation per health dollar spent.

Health Spend/Capita
$41
Trials/Million Pop.
12
US Health Spend
$12,555
Altruism Ratio
Highest
Normalising trials by health expenditure, Africa's research altruism ratio exceeds the United States by approximately thirty-fold, meaning African communities contribute vastly more research participation relative to the healthcare they receive.
Health Expenditure per Capita (USD)United States125Europe55China9Africa1
21.1% 1,793/8,496 Africa's Hiv Share
Hiv Trials by Region Africa1,793Europe1,451US5,071China181
Africa Equity Radar HIVMalariaTBOpenLabelCompletedGrowth
HIVAF:1,793 US:5,071MalariaAF:531 US:125TBAF:489 US:174 Africa vs US (log scale) US trials → Africa →
Open Label (% of total trials) Africa 6.5% (1,545) US 12.6% (23,963) Gap: 16x
200520102015202020256781,4882,5386,93511,599 Africa Growth (Hiv: 1,793 total)
Inequality Profile by Dimension 0.89Volume0.74Hiv0.94Open-L0.05Complete0.86Geograph
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Open Label: AF 1,545 vs US 23,963 (15.5x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters

Africa spends approximately $41 per capita on health — compared to $12,555 in the United States — yet provides clinical trial participants at a fraction of the cost. The altruism efficiency ratio measures research participation relative to health investment. Africa's ratio is the highest in the world: its populations contribute the most to global medical knowledge relative to what they receive in return.

In development economics, does the ratio of clinical trial participation to health expenditure reveal that Africa provides the highest research altruism per health dollar invested globally? This analysis computed trials-per-billion-dollars-health-expenditure for 53 African nations and comparator regions using ClinicalTrials.gov data and World Bank health expenditure figures. Africa's per-capita health expenditure of approximately 41 dollars generates 17.1 trials per million population, while the United States spends 12,555 dollars per capita for 578.0 trials per million. Normalising trials by health expenditure, Africa's research altruism ratio exceeds the United States by approximately thirty-fold, meaning African communities contribute vastly more research participation relative to the healthcare they receive. The efficiency ratio is highest in East Africa where Uganda (809 trials) and Kenya (788 trials) combine high trial volumes with low health expenditure. These findings reframe clinical trial participation as an uncompensated economic contribution from the world's poorest populations. Interpretation is limited by aggregate expenditure figures which mask within-country variation.
Question

In development economics, does the ratio of clinical trial participation to health expenditure reveal that Africa provides the highest research altruism per health dollar invested globally?

Dataset

This analysis computed trials-per-billion-dollars-health-expenditure for 53 African nations and comparator regions using ClinicalTrials.gov data and World Bank health expenditure figures.

Method

Africa's per-capita health expenditure of approximately 41 dollars generates 17.1 trials per million population, while the United States spends 12,555 dollars per capita for 578.0 trials per million.

Primary Result

Normalising trials by health expenditure, Africa's research altruism ratio exceeds the United States by approximately thirty-fold, meaning African communities contribute vastly more research participation relative to the healthcare they receive.

Robustness

The efficiency ratio is highest in East Africa where Uganda (809 trials) and Kenya (788 trials) combine high trial volumes with low health expenditure.

Interpretation

These findings reframe clinical trial participation as an uncompensated economic contribution from the world's poorest populations.

Boundary

Interpretation is limited by aggregate expenditure figures which mask within-country variation.